Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

Andrea Gaedigk to Aryl Hydrocarbon Hydroxylases

This is a "connection" page, showing publications Andrea Gaedigk has written about Aryl Hydrocarbon Hydroxylases.

 
Connection Strength
  
 
 
3.079
  
  1. Zubiaur P, Leeder JS, Abad-Santos F, Gaedigk A. Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?" Clin Pharmacol Ther. 2024 Feb; 115(2):184.
    View in: PubMed
    Score: 0.945
  2. Twist GP, Gaedigk R, Leeder JS, Gaedigk A. High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics. 2013 Jun; 14(8):913-22.
    View in: PubMed
    Score: 0.458
  3. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos. 2010 Jun; 38(6):894-7.
    View in: PubMed
    Score: 0.366
  4. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001 Oct; 79(10):841-7.
    View in: PubMed
    Score: 0.204
  5. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000 Feb; 38(2):61-8.
    View in: PubMed
    Score: 0.182
  6. Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics. 2013 Aug; 23(8):403-14.
    View in: PubMed
    Score: 0.116
  7. Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P, Dr?gem?ller BI, Wright GE, Warnich L, Labuschagne CD, van Schalkwyk A, Gaedigk A, Pepper MS. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013 Jan 29; 14:20.
    View in: PubMed
    Score: 0.112
  8. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M?ller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May; 93(5):402-8.
    View in: PubMed
    Score: 0.112
  9. Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol. 2006 Jun; 62(6):431-6.
    View in: PubMed
    Score: 0.070
  10. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug; 314(2):626-35.
    View in: PubMed
    Score: 0.065
  11. Kim MJ, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS. Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol. 2004 Sep; 44(9):966-73.
    View in: PubMed
    Score: 0.062
  12. Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 Jun; 44(6):570-6.
    View in: PubMed
    Score: 0.061
  13. Kearns GL, Andersson T, James LP, Gaedigk A, Kraynak RA, Abdel-Rahman SM, Ramabadran K, van den Anker JN. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol. 2003 Aug; 43(8):840-8.
    View in: PubMed
    Score: 0.058
  14. Kim MJ, Bertino JS, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002 Aug; 72(2):192-9.
    View in: PubMed
    Score: 0.054
  15. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul; 41(7):715-22.
    View in: PubMed
    Score: 0.050
  16. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
    View in: PubMed
    Score: 0.048
  17. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
    View in: PubMed
    Score: 0.044
  18. Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 1998 Jun 12; 710(1-2):143-8.
    View in: PubMed
    Score: 0.041
  19. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr; 50(4):1130-5.
    View in: PubMed
    Score: 0.017
  20. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.